135 related articles for article (PubMed ID: 2109264)
1. Fibrinolytic responses to 1-desamino-8-D-arginine-vasopressin in patients with congenital nephrogenic diabetes insipidus.
Knoers N; Brommer EJ; Willems H; van Oost BA; Monnens LA
Nephron; 1990; 54(4):322-6. PubMed ID: 2109264
[TBL] [Abstract][Full Text] [Related]
2. 1-Desamino-8-D-arginine vasopressin (DDAVP) in patients with congenital nephrogenic diabetes insipidus.
Brink HS; Derkx FH; Boomsma F; Brommer EJ; Schalekamp MA
Neth J Med; 1993 Aug; 43(1-2):5-12. PubMed ID: 8232694
[TBL] [Abstract][Full Text] [Related]
3. Normal homeostasis of fibrinolysis in nephrogenic diabetes insipidus in spite of defective V2- receptor-mediated responses of tissue plasminogen activator release.
Brommer EJ; Brink H; Derkx FH; Schalekamp MA; Stibbe J
Eur J Clin Invest; 1990 Feb; 20(1):72-8. PubMed ID: 2138555
[TBL] [Abstract][Full Text] [Related]
4. Hemodynamic and coagulation responses to 1-desamino[8-D-arginine] vasopressin in patients with congenital nephrogenic diabetes insipidus.
Bichet DG; Razi M; Lonergan M; Arthus MF; Papukna V; Kortas C; Barjon JN
N Engl J Med; 1988 Apr; 318(14):881-7. PubMed ID: 2965301
[TBL] [Abstract][Full Text] [Related]
5. Normal fibrinolytic responses to 1-desamino-8-D-arginine vasopressin in patients with nephrogenic diabetes insipidus caused by mutations in the aquaporin 2 gene.
van Lieburg AF; Knoers VV; Mallmann R; Proesmans W; van den Heuvel LP; Monnens LA
Nephron; 1996; 72(4):544-6. PubMed ID: 8730418
[TBL] [Abstract][Full Text] [Related]
6. A variant of nephrogenic diabetes insipidus: V2 receptor abnormality restricted to the kidney.
Knoers N; Monnens LA
Eur J Pediatr; 1991 Mar; 150(5):370-3. PubMed ID: 1828422
[TBL] [Abstract][Full Text] [Related]
7. Fibrinolytic and haemostatic responses to desamino-D-arginine vasopressin (DDAVP) administered by intravenous and subcutaneous routes in healthy subjects.
MacGregor IR; Roberts EM; Prowse CV; Broomhead AF; Ozolins M; Litka P
Thromb Haemost; 1988 Feb; 59(1):34-9. PubMed ID: 3129807
[TBL] [Abstract][Full Text] [Related]
8. Impaired fibrinolytic response to DDAVP in patients with von Willebrand's disease.
Sultan Y; Loyer F; Venot A
Nouv Rev Fr Hematol (1978); 1992; 34(1):55-60. PubMed ID: 1523100
[TBL] [Abstract][Full Text] [Related]
9. Absent factor VIII response to synthetic vasopressin analogue (DDAVP) in nephrogenic diabetes insipidus.
Kobrinsky NL; Doyle JJ; Israels ED; Winter JS; Cheang MS; Walker RD; Bishop AJ
Lancet; 1985 Jun; 1(8441):1293-4. PubMed ID: 2860491
[TBL] [Abstract][Full Text] [Related]
10. Two distinct pathophysiological mechanisms in congenital nephrogenic diabetes insipidus.
Moses AM; Miller JL; Levine MA
J Clin Endocrinol Metab; 1988 Jun; 66(6):1259-64. PubMed ID: 3131381
[TBL] [Abstract][Full Text] [Related]
11. Normal response of factor VIII and von Willebrand factor to 1-deamino-8D-arginine vasopressin in nephrogenic diabetes insipidus.
Brenner B; Seligsohn U; Hochberg Z
J Clin Endocrinol Metab; 1988 Jul; 67(1):191-3. PubMed ID: 3132483
[TBL] [Abstract][Full Text] [Related]
12. Fibrinolytic capacity following stimulation with desmopressin acetate in patients with diabetes mellitus.
Grant MB; Fitzgerald C; Guay C; Lottenberg R
Metabolism; 1989 Sep; 38(9):901-7. PubMed ID: 2505017
[TBL] [Abstract][Full Text] [Related]
13. Normal tissue plasminogen activator and plasminogen activator inhibitor activity in plasma from patients with type 1 diabetes mellitus.
Vicari AM; Viganó D'Angelo S; Testa S; Comi G; Galardi G; Orsi E; D'Angelo A
Horm Metab Res; 1992 Nov; 24(11):516-9. PubMed ID: 1452117
[TBL] [Abstract][Full Text] [Related]
14. Fibrinolytic shut-down after surgery: impairment of the balance between tissue-type plasminogen activator and its specific inhibitor.
D'Angelo A; Kluft C; Verheijen JH; Rijken DC; Mozzi E; Mannucci PM
Eur J Clin Invest; 1985 Dec; 15(6):308-12. PubMed ID: 3938400
[TBL] [Abstract][Full Text] [Related]
15. Different tissue plasminogen activator release in the arm and leg during venous occlusion is equalized after DDAVP infusion.
Keber D; Stegnar M; Kluft C
Thromb Haemost; 1990 Feb; 63(1):72-5. PubMed ID: 2111049
[TBL] [Abstract][Full Text] [Related]
16. Epinephrine and dDAVP administration in patients with congenital nephrogenic diabetes insipidus. Evidence for a pre-cyclic AMP V2 receptor defective mechanism.
Bichet DG; Razi M; Arthus MF; Lonergan M; Tittley P; Smiley RK; Rock G; Hirsch DJ
Kidney Int; 1989 Nov; 36(5):859-66. PubMed ID: 2559238
[TBL] [Abstract][Full Text] [Related]
17. The fibrinolytic system in the hemolytic uremic syndrome: in vivo and in vitro studies.
van de Kar NC; van Hinsbergh VW; Brommer EJ; Monnens LA
Pediatr Res; 1994 Aug; 36(2):257-64. PubMed ID: 7970942
[TBL] [Abstract][Full Text] [Related]
18. Fibrinolytic response in normal subjects to venous occlusion and DDAVP infusion.
Cugno M; Uziel L; Fabrizi I; Bottasso B; Maggiolini F; Agostoni A
Thromb Res; 1989 Dec; 56(5):625-34. PubMed ID: 2516662
[TBL] [Abstract][Full Text] [Related]
19. Influence of 1-desamino-8-D-vasopressin on endogenous fibrinolysis, haemodynamics and liver blood flow in healthy subjects.
Burggraaf J; Schoemaker HC; Kroon JM; Huisman L; Kluft C; Cohen AF
Clin Sci (Lond); 1994 May; 86(5):497-503. PubMed ID: 8033503
[TBL] [Abstract][Full Text] [Related]
20. Hyperuricemia as a clue for central diabetes insipidus (lack of V1 effect) in the differential diagnosis of polydipsia.
Decaux G; Prospert F; Namias B; Soupart A
Am J Med; 1997 Nov; 103(5):376-82. PubMed ID: 9375705
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
